Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and
safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced
solid tumors. The primary hypothesis of this study is that subjects will have a better
objective response rate (ORR) when treated with Envafolimab plus Lenvatinib than SOC.